Global Dengue Drugs Market By Distribution Channel (Hospitals, Clinics, Pharmacies, Others); By Type (Rx, OTC); By Drug Class (Acetaminophen, Rehydration therapy, Others); By Route of Administration (Oral, Intravenous); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Amidst absence of any proven effective vaccine for protecting humans against dengue, demand for supportive drugs against dengue is surging high. Dengue is a mosquito-borne viral infection which causes severe flu-like illness and sometimes also leads to a potentially lethal complication which might cause death. Dengue fever is spread by the female Aedes mosquito which has been infected with dengue fever virus. Pharmaceutical companies have been striving to develop a safe, effective and affordable vaccine against dengue. The Dengvaxia vaccine of Sanofi introduced in Philippines on December 22, 2015, was approved for dengue immunization by various national and international authorities including World Health Organization, U.S Centers for Disease Control and Prevention and others. But the later in February 2017 the Philippines Department of Justice said that they have found evidence showing that the vaccine can cause severe illness in people who hadn't previously been infected by the dengue. This probed an investigation from World Health Organization creating concerns for the use of this vaccine against dengue. However, this absence of an effective vaccine against dengue has led to an upsurge in the demand for supportive drugs as the patients with dengue infection continue to rise. Drugs are offered for preventing the progression of symptoms and onset of the severe manifestations of dengue. The people infected with dengue virus show symptoms such as high fever, headache behind the eyes, nausea, vomiting, skin rash, muscle and joint pain. These patients are administered with symptomatic drugs and most probably Acetaminophen to treat the fever. Thus, the high flow of dengue patients amidst the absence of an effective and proven vaccine for immunization continues to spur the demand in dengue drugs market across the globe.
Despite the rapid maturation of the research and development infrastructure for dengue drugs and the increasing frequency of dengue inhibitors reported in the scientific literature, the potential size of the market for dengue drugs has not been articulated. In the present work, extrapolating from publicly available information, we explored the economic burden attributable to dengue, the impact of dengue vaccines on clinical case loads, a possible alternative to tiered pricing for products for neglected diseases, and defined the maximum potential market for a dengue drug. Our projections suggest that in 2006, the annual global burden of dengue was US $1.7billion. Our proposed alternative to existing tiered pricing structures is that
The growing low income housing and slums in the urban areas across the globe are a leading cause for the high flow of patients with dengue infection. The poorly sanitized surroundings of these households create futile breeding grounds for the Aedes aegypti mosquitoes which are the main vectors for dengue infection. The World Health Organization states that the rampant urbanization has contributed to 30 folds increase in dengue cases since last few decades which affects up to 50 – 100 million patients annually across more than 100 endemic countries (countries which have not effectively stopped the spread of virus). These numbers have put more than half of the global population at risk of getting infected by dengue and thus, imposing a high economic burden on the countries which includes direct medical costs to the health system or individuals, non-medical costs related to the treatment of the disease and lost productivity. These high number of patients with dengue infection are propelling the demand in dengue market across the globe.
Dengue is classified as a neglected disease by the World Health Dengue. Despite the rapid spread of this infectious disease, global attention from government agencies and other healthcare entities has been negligible towards this infection. This factors have negatively affected the development of high quality effective drugs for treatment of dengue thus, hindering the growth of global dengue drugs market.
The recent outbreak of COVID-19 pandemic has affected around 150 countries across continents with more than 13. 5 million active cases registered till July 2020. This pandemic has created high demand for pharmaceutical drugs to treat the patients with active symptoms of coronavirus infection. Researchers and medical professionals around the globe have highlighted the potential of dengue drugs in treatment of coronavirus infection. For instance, a research group from Department of Pharmacy at Qingdao Municipal Hospital of China has released a research study stating that Chloroquine drug, used for treatment of dengue and malaria, has shown to have efficacy and acceptable safety for treatment of COVID-19 associated pneumonia. National Health Commission of the People's Republic of China is going to include this drug in their recommendation in Guidelines for Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19. These research findings also triggered high demand for chloroquine drug imports by countries such as S, Spain, Germany, Bahrain, Brazil, Nepal, Bhutan and many others. Also, the Indian based pharmaceutical company, Sun Pharmaceutical Industries Ltd. has submitted a proposal to the government for conducting phase 2 trials of its plant based dengue drug to treat COVID-19 patients. These research studies focused on using dengue drugs for the treatment of COVID-19 patients are propelling the growth of dengue drugs market across the globe.
Drug Class Outlook:
The acetaminophen drug class dominates the global dengue drugs market. In the early stages of dengue fever patients are given acetaminophen for alleviating fever or pain. The U.S Centers for Disease Control and Prevention agency also recommends use of acetaminophen in treatment of dengue patients over aspirin or ibuprofen. The agency also recommends also recommends oral intake of normal fluids such as water or energy drinks, which decrease the demand for rehydration therapy drugs as compared to acetaminophen.
Regional Outlook:
Tropical countries of Latin America and Asia Pacific region contributed significant share in global dengue drugs market in 2018. The World Health Organization says that dengue is a leading cause of death among children and adults in these tropical countries. The Asian countries are actively striving to curb these rate of dengue infection. The country of Philippines initiated the world’s first dengue immunization program in 2016. Also Dr. Soumya Swaminathan, deputy director general at the World Health Organisation, said in January 2019 that the increased funding and investments by Indian Council of Medical Research towards research and development of treatment in neglected diseases including dengue will boost India’s position. These steps taken by the regional countries will boost the share of Asia Pacific region in global dengue drugs market in upcoming years.
In terms of revenue, global dengue drugs market is anticipated to grow at a CAGR of 2.6% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Dengue Drugs Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of dengue drugs market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the dengue drugs market are AbbVie Inc., ABIVAX, GSK group of companies, Johnson & Johnson Services, Inc., Micro Labs Ltd., Pfizer Inc., Sanofi, Sun Pharma and Takeda Pharmaceutical Company Limited amongst others.
Global Dengue Drugs Market:
By Distribution Channel
- Hospitals
- Clinics
- Pharmacies
- Others
By Type
- Rx
- OTC
By Drug Class
- Acetaminophen
- Rehydration therapy
- Others
By Route of Administration
- Oral
- Intravenous
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Global Dengue Drugs Market By Distribution
Channel (Hospitals, Clinics, Pharmacies, Others); By Type (Rx, OTC); By Drug
Class (Acetaminophen,
Rehydration therapy, Others);
By Route of Administration (Oral, Intravenous); By Region (U.S., Canada,
Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic
Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands,
Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South
Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of
Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle
East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights,
Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Amidst absence of any proven effective
vaccine for protecting humans against dengue, demand for supportive drugs
against dengue is surging high. Dengue is a mosquito-borne viral infection which
causes severe flu-like illness and sometimes also leads to a potentially lethal
complication which might cause death. Dengue fever is spread by the female
Aedes mosquito which has been infected with dengue fever virus. Pharmaceutical
companies have been striving to develop a safe, effective and affordable vaccine
against dengue. The Dengvaxia vaccine of Sanofi introduced in Philippines on
December 22, 2015, was approved for dengue immunization by various national and
international authorities including World Health Organization, U.S Centers for
Disease Control and Prevention and others. But the later in February 2017 the Philippines
Department of Justice said that they have found evidence showing that the
vaccine can cause severe illness in people who hadn't previously been infected
by the dengue. This probed an investigation from World Health Organization
creating concerns for the use of this vaccine against dengue. However, this
absence of an effective vaccine against dengue has led to an upsurge in the
demand for supportive drugs as the patients with dengue infection continue to
rise. Drugs are offered for preventing the progression of symptoms and onset of
the severe manifestations of dengue. The people infected with dengue virus show
symptoms such as high fever, headache behind the eyes, nausea, vomiting, skin
rash, muscle and joint pain. These patients are administered with symptomatic
drugs and most probably Acetaminophen to treat the fever. Thus, the high flow
of dengue patients amidst the absence of an effective and proven vaccine for
immunization continues to spur the demand in dengue drugs market across the
globe.
Despite the rapid maturation
of the research and development infrastructure for dengue drugs and the
increasing frequency of dengue inhibitors reported in the scientific
literature, the potential size of the market for dengue drugs has not been
articulated. In the present work, extrapolating from publicly available
information, we explored the economic burden attributable to dengue, the impact
of dengue vaccines on clinical case loads, a possible alternative to tiered
pricing for products for neglected diseases, and defined the maximum potential
market for a dengue drug. Our projections suggest that in 2006, the annual
global burden of dengue was US $1.7billion. Our proposed alternative to
existing tiered pricing structures is that
The growing low income housing
and slums in the urban areas across the globe are a leading cause for the high
flow of patients with dengue infection. The poorly sanitized surroundings of
these households create futile breeding grounds for the Aedes aegypti
mosquitoes which are the main vectors for dengue infection. The World Health
Organization states that the rampant urbanization has contributed to 30 folds increase
in dengue cases since last few decades which affects up to 50 – 100 million
patients annually across more than 100 endemic countries (countries which have
not effectively stopped the spread of virus). These numbers have put more than
half of the global population at risk of getting infected by dengue and thus,
imposing a high economic burden on the countries which includes direct medical
costs to the health system or individuals, non-medical costs related to the
treatment of the disease and lost productivity. These high number of patients
with dengue infection are propelling the demand in dengue market across the
globe.
Dengue is classified as a
neglected disease by the World Health Dengue. Despite the rapid spread of this
infectious disease, global attention from government agencies and other
healthcare entities has been negligible towards this infection. This factors
have negatively affected the development of high quality effective drugs for
treatment of dengue thus, hindering the growth of global dengue drugs market.
The recent outbreak of
COVID-19 pandemic has affected around 150 countries across continents with more
than 13. 5 million active cases registered till July 2020. This pandemic has
created high demand for pharmaceutical drugs to treat the patients with active
symptoms of coronavirus infection. Researchers and medical professionals around
the globe have highlighted the potential of dengue drugs in treatment of
coronavirus infection. For instance, a research group from Department of
Pharmacy at Qingdao Municipal Hospital of China has released a research study
stating that Chloroquine drug, used for treatment of dengue and malaria, has shown
to have efficacy and acceptable safety for treatment of COVID-19 associated
pneumonia. National Health Commission of the People's Republic of China is
going to include this drug in their recommendation in Guidelines for
Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19. These
research findings also triggered high demand for chloroquine drug imports by
countries such as S, Spain, Germany, Bahrain, Brazil, Nepal, Bhutan and many
others. Also, the Indian based pharmaceutical company, Sun Pharmaceutical
Industries Ltd. has submitted a proposal to the government for conducting phase
2 trials of its plant based dengue drug to treat COVID-19 patients. These
research studies focused on using dengue drugs for the treatment of COVID-19
patients are propelling the growth of dengue drugs market across the globe.
Drug Class Outlook:
The acetaminophen drug class
dominates the global dengue drugs market. In the early stages of dengue fever
patients are given acetaminophen for alleviating fever or pain. The U.S Centers
for Disease Control and Prevention agency also recommends use of acetaminophen
in treatment of dengue patients over aspirin or ibuprofen. The agency also
recommends also recommends oral intake of normal fluids such as water or energy
drinks, which decrease the demand for rehydration therapy drugs as compared to acetaminophen.
Regional Outlook:
Tropical countries of Latin
America and Asia Pacific region contributed significant share in global dengue
drugs market in 2018. The World Health Organization says that dengue is a
leading cause of death among children and adults in these tropical countries.
The Asian countries are actively striving to curb these rate of dengue
infection. The country of Philippines initiated the world’s first dengue
immunization program in 2016. Also Dr. Soumya Swaminathan, deputy director
general at the World Health Organisation, said in January 2019 that the
increased funding and investments by Indian Council of Medical Research towards
research and development of treatment in neglected diseases including dengue
will boost India’s position. These steps taken by the regional countries will
boost the share of Asia Pacific region in global dengue drugs market in
upcoming years.
In terms of revenue, global dengue
drugs market is anticipated to grow at a CAGR of 2.6% over the forecast period.
The study analyses the market in terms of revenue across all the major regions,
which have been bifurcated into countries.
Global Dengue Drugs Market Revenue & Forecast, (US$
Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative
research of dengue
drugs market,
as well as provides comprehensive insights and development methods adopted by
the key contenders. The report also offers extensive research on the key
players in this market and details on the competitiveness of these players. Key
business strategies such as mergers and acquisitions (M&A), affiliations,
collaborations, and contracts adopted by these major market participants are
also recognized and analyzed in the report. For each company, the report
studies their global presence, competitors, service offerings and specification
amongst others.
Some of the players operating in the dengue drugs market are AbbVie
Inc., ABIVAX, GSK group of companies, Johnson & Johnson Services, Inc.,
Micro Labs Ltd., Pfizer Inc., Sanofi, Sun Pharma and Takeda Pharmaceutical
Company Limited amongst others.
Global Dengue Drugs Market:
o By Distribution Channel
§ Hospitals
§ Clinics
§ Pharmacies
§ Others
o By Type
§ Rx
§ OTC
o By Drug Class
§ Acetaminophen
§ Rehydration
therapy
§ Others
o By Route of Administration
§ Oral
§ Intravenous
o By Region
§ North
America
·
U.S
·
Canada
·
Mexico
·
Rest of North America
§ Europe
·
France
·
The UK
·
Spain
·
Germany
·
Italy
·
Nordic Countries
ü Denmark
ü Finland
ü Iceland
ü Sweden
ü Norway
·
Benelux Union
ü Belgium
ü The
Netherlands
ü Luxembourg
·
Rest of Europe
§ Asia
Pacific
·
China
·
Japan
·
India
·
New Zealand
·
Australia
·
South Korea
·
Southeast Asia
ü Indonesia
ü Thailand
ü Malaysia
ü Singapore
ü Rest
of Southeast Asia
·
Rest of Asia Pacific
§ Middle
East and Africa
·
Saudi Arabia
·
UAE
·
Egypt
·
Kuwait
·
South Africa
·
Rest of Middle East & Africa
§ Latin
America
·
Brazil
·
Argentina
·
Rest of Latin America
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.